September 20, 2017

Biohaven partners with Alzheimer's research group on drug trial

New Haven's Biohaven Pharmaceutical Holding Co. Ltd. is partnering with an Alzheimer's disease research consortium on a clinical trial of an investigational drug.

Biohaven is developing the investigational drug trigriluzole, which is intended to control glutamate dysfunction, which studies have shown plays a role in Alzheimer's disease.

As part of the study collaboration with Alzheimer's Disease Cooperative Study, Biohaven will fund a phase 2 clinical trial to evaluate the efficacy and safety of using trigriluzole in patients with mild-to-moderate Alzheimer's.

Free E-Newsletters

Sign up now for our daily and weekly
e-newsletters! Click Here

Today's Poll Is Connecticut a smart location for a second Amazon headquarters?<>
Most Popular on Facebook
Copyright 2017 New England Business Media